Product Center

01 Aitai Bio | Related R&D Technical Data Invention Patent Related technical information New Uses of Polymerase I Inhibitors The patent of the present invention revolves around new uses of Polymerase I inhibitors, and the certificate indicates that this technology has obtained authorization for a Chinese invention patent. This is only a display of its patent and research and development data, and does not represent a description of the specific product's efficacy. Patent No.: ZL 2018 1 0588234.0 | Patent Holder: Sun Yat-sen University | Authorization Announcement No.: CN 108904508 B | Authorization Announcement Date: March 12, 2021

01 Aitai Bio | Related R&D Technical Data Invention Patent Cell membrane nanovesicle related technologies A cell membrane nanovesicle encapsulating an immunosuppressant and overexpressing PD-L1, its preparation method and application. The invention patent relates to cell membrane nanovesicles that encapsulate immunosuppressants and overexpress PD-L1, as well as related preparation methods and applications, reflecting the research and technological accumulation in the direction of cell membrane nanovesicles. Patent No.: ZL 2020 1 0601231.3 | Patent Holder: Sun Yat-sen University, Shenzhen | Authorization Announcement No.: CN 111920769 B | Authorization Announcement Date: September 13, 2022

01 Aitai Bio | Related R&D Technical Data Invention Patent Nanocarrier related technologies A nucleolar-targeted nanocarrier carrying a Polymerase I inhibitor, its preparation method and application The patent relates to nucleolus-targeting nanocarriers carrying Polymerase I inhibitors, as well as their preparation methods and applications, belonging to the patent achievements in the direction of nanocarriers and related preparation technologies. Patent No.: ZL 2018 1 0332801.6 | Patent Holder: Sun Yat-sen University | Authorization Announcement No.: CN 109045304 B | Authorization Announcement Date: April 5, 2022

01 Aitai Bio | Related R&D Technical Data Invention Patent PD-1 cell membrane nanovesicle related technologies Application of PD-1 cell membrane nanovesicles combined with stem cell membranes in the postoperative treatment of malignant melanoma The title of the invention patent indicates that its technical content involves the combined application of PD-1 cell membrane nanovesicles and stem cell membrane sheets. The page only displays the technical content contained in the patent and does not extend to interpret its clinical effects. Patent No.: ZL 2022 1 0453760.2 | Patent Holder: Sun Yat-sen University, Shenzhen; Sun Yat-sen University | Authorization Announcement No.: CN 114869911 B | Authorization Announcement Date: September 1, 2023

01 Aitai Bio | Related R&D Technical Data Invention Patent Exosome-related technologies Novel Uses of PD-L1 Exosomes The invention patent revolves around new uses of PD-L1 exosomes, reflecting the research and development achievements and intellectual property accumulation in the field of exosomes. The specific technical content and applicable scope are subject to the original patent documents. Patent No.: ZL 2019 1 1205272.4 | Patent Holder: Sun Yat-sen University, Shenzhen | Authorization Announcement No.: CN 111643523 B | Authorization Announcement Date: September 1, 2023

01 Aitai Bio | Related R&D Technical Data Invention Patent Immune-related research and development technologies Application of PD-L1/CTLA-4 in the preparation of immunosuppressants The invention patent relates to the application of PD-L1/CTLA-4 in the preparation of immunosuppressants, and the certificate indicates that this technology has obtained authorization for a Chinese invention patent. Patent No.: ZL 2019 1 1397890.3 | Patent Holder: Sun Yat-sen University, Shenzhen | Authorization Announcement No.: CN 111214646 B | Authorization Announcement Date: August 1, 2023

01 Aitai Bio | Related R&D Technical Data Invention Patent Immune-related research and development technologies Application of C₂₇H₂₇N₇O₂S in the Preparation of Agents to Inhibit Rejection of Organ Allogeneic Transplantation The title of the invention patent indicates that its research content involves the application of the specific compound C₂₇H₂₇N₇O₂S in the direction related to organ transplantation rejection, belonging to relevant immunological research and technological achievements. Patent No.: ZL 2019 1 1115394.4 | Patent Holder: Sun Yat-sen University, Shenzhen | Authorization Announcement No.: CN 110934876 B | Authorization Announcement Date: July 28, 2023

01 Aitai Bio | Related R&D Technical Data Invention Patent Nanovesicle related technologies A fusion nanovesicle, its preparation method and application This invention patent relates to fused nanovesicles and their preparation methods and applications, showcasing patented technological achievements in the preparation and application of nanovesicles. Patent No.: ZL 2022 1 1059311.6 | Patent Holder: Sun Yat-sen University | Authorization Announcement No.: CN 115381880 B | Authorization Announcement Date: May 12, 2023

01 Aitai Bio | Related R&D Technical Data Invention Patent Immune-related research and development technologies Application of CX-5461 in the treatment of immune rejection in kidney transplantation The title of the invention patent indicates that its research direction involves the application of CX-5461 in relation to kidney transplant immune rejection. This is only a presentation of patent technical data and does not represent any additional explanation regarding clinical indications or treatment effects. Patent No.: ZL 2022 1 0514892.1 | Patent Holder: Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University | Authorization Announcement No.: CN 114652729 B | Authorization Announcement Date: March 21, 2023

01 Aitai Bio | Exosome-related technologies Design patent Exosome purification equipment Exosome purification equipment appearance design patent The design patent pertains to the product appearance design of "exosome purification equipment," with the patent holder being Shenzhen Aitai Biomedical Technology Co., Ltd. It reflects the company's product design and intellectual property layout in the field of exosome-related equipment. Patent No.: ZL 2023 3 0853529.8 | Patent Holder: Shenzhen Aitai Biomedical Technology Co., Ltd. | Authorization Announcement No.: CN 308837966 S | Authorization Announcement Date: September 13, 2024

01 Aitai Bio | Exosome-related technologies Utility model patent equipment related to cell exosome concentration A pressure regulating device for concentrated exosome liquid The utility model patent relates to a liquid pressure regulating device in the process of extracellular vesicle concentration, with the patent holder being Shenzhen Aitai Biomedical Technology Co., Ltd., belonging to the technical achievements related to exosome concentration equipment. Patent No.: ZL 2023 2 3409775.8 | Patent Holder: Shenzhen Aitai Biomedical Technology Co., Ltd. | Authorization Announcement No.: CN 221566099 U | Authorization Announcement Date: August 20, 2024

01 Aitai Bio | Microbial R&D Technology Invention Patent related technologies for fermentation culture of Lactobacillus rhamnosus High-density Lactobacillus rhamnosus fermentation medium, its culture method, and fermentation process The invention patent relates to a high-density Lactobacillus rhamnosus fermentation culture medium, as well as the corresponding culture method and fermentation process, reflecting the technological research and development achievements in the direction of microbial culture and fermentation processes. Patent No.: ZL 2023 1 0090776.6 | Patent Holder: Shenzhen Aitai Biomedical Technology Co., Ltd. | Authorization Announcement No.: CN 116555072 B | Authorization Announcement Date: June 25, 2024 | Certificate Recorded Applicant at the Time of Application: Shenzhen Finja Biotechnology Co., Ltd.

01 Aitai Bio | Exosome-related technologies Utility model patent equipment related to cell exosome concentration An automatic exhaust device and concentration equipment for an exosome concentrator capsule filter. The utility model patent relates to an automatic exhaust device and concentration equipment for an extracellular vesicle concentrated bag filter, with the patent holder being Shenzhen Aitai Biomedical Technology Co., Ltd., belonging to the technical achievements related to extracellular vesicle concentration equipment. Patent No.: ZL 2024 2 0059173.X | Patent Holder: Shenzhen Aitai Biomedical Technology Co., Ltd. | Authorization Announcement No.: CN 221451933 U | Authorization Announcement Date: August 02, 2024

01 Shunbaike | Case Studies Use Case | Observation of Abrasions Shunbaike Lysozyme Multipurpose Disinfectant Adult abrasion treatment record | Observation period: approximately 48 hours The original case data records a 46-year-old adult who used Shun Baike Lysozyme Multi-Purpose Disinfectant after sustaining a bruise. The images document the local appearance changes on July 26, July 27, and July 28. The original text states, "Completely healed 48 hours after the bruise, using only Shun Baike Lysozyme Multi-Purpose Disinfectant." This section only presents the actual usage record according to the original case content and does not represent that all users will achieve the same results. Source: Actual usage case data provided by Shunbaike | Image recording times: July 26, 10:00 AM, July 27, 12:00 PM, July 28, 10:00 AM.

01 Shunbaike | Related Patent Technologies Invention Patent Shunbaike series related technical information A composition, preparation method and application The invention patent relates to a composition and its preparation method and application. The patent certificate shows that the patent holder is Beijing Shunlei Technology Co., Ltd., which can be presented as relevant research and development and technical background information for Shunbaike. Since this certificate does not directly indicate its correspondence to a specific Shunbaike product, the patent is not directly linked to a single product here. Patent No.: ZL 2023 1 1633509.5 | Patent Holder: Beijing Shunlei Technology Co., Ltd. | Authorization Announcement No.: CN 117643311 B | Authorization Announcement Date: September 27, 2024.

01 Shunbaike | Case Studies Use Case | Child Trauma Observation Shunbaike Lysozyme Multipurpose Disinfectant Childhood scalp trauma use record | 7-day observation The original case record documents the appearance changes of a two-and-a-half-year-old child's scalp injury after being stitched with more than ten stitches, during the use of Shun Baike lysozyme multi-purpose disinfectant. The images show the local condition on June 8, June 11, and June 14. In the attached chat record, the case provider states that no other medications were used during this period, and a daily spraying method was adopted. This page only presents the original case record and does not draw general efficacy conclusions from individual case results. Source: Child trauma cases and related communication records provided by Shunbaike | Original data record observation period of approximately 7 days.

01 Zhongke Yikang | Probiotic R&D Technology Invention Patent Sleep management related probiotic technology A compound probiotic fermentation composition for improving sleep quality and its application The invention patent revolves around a composite probiotic fermentation composition aimed at improving sleep quality and its applications. It belongs to the patent technology achievements of Zhongke Yikang in the research direction related to probiotic fermentation compositions and sleep. The page only displays the research and development direction stated in the patent and does not equate the patent name directly with the actual usage effects of specific products. Patent No.: ZL 2022 1 1665900.9 | Patent Holder: Zhongke Yikang (Beijing) Biotechnology Co., Ltd. | Authorization Announcement No.: CN 116121130 B | Authorization Date: October 8, 2024.

01 Zhongke Yikang | Probiotic R&D Technology Invention Patent Probiotic technology related to weight management A probiotic and prebiotic composition for promoting lean physique and its application The invention patent relates to a combination of probiotics and prebiotics and its application in "forming a lean physique," reflecting Zhongke Yikang's technical accumulation in the fields of probiotics, prebiotics, and related microecological research. The specific scope of patent protection and technical content shall be subject to the original patent documents. Patent No.: ZL 2019 1 0385918.5 | Patent Holder: Zhongke Yikang (Beijing) Biotechnology Co., Ltd. | Authorization Announcement No.: CN 110151796 B | Authorization Date: February 4, 2020.

01 Zhongke Yikang | Patented Strains Technology Invention Patent | Patented Strains ZK-77 Bifidobacterium animalis related technologies Animal Bifidobacterium strain ZK-77 is used to inhibit pathogens, alleviate inflammation, and regulate gut microbiota balance. The invention patent relates to the animal bifidobacterium strain ZK-77. The technical direction described in the patent includes inhibiting pathogenic bacteria, alleviating inflammation, and regulating microbial balance. This patent reflects Zhongke Yikang's technological achievements in the selection of specific probiotic strains and research in microecology. Patent No.: ZL 2022 1 0119972.7 | Patent Holder: Zhongke Yikang (Beijing) Biotechnology Co., Ltd. | Authorization Announcement No.: CN 114164158 B | Authorization Date: June 3, 2022.

01 Zhongke Yikang | Patented Strains Technology Invention Patent | Patented Strains ZK-88 Lactobacillus salivarius related technologies Lactobacillus salivarius strain ZK-88 is used to suppress inflammation, relieve swollen and painful gums, and improve the balance of oral flora. The invention patent relates to the saliva Lactobacillus strain ZK-88. The research directions mentioned in the patent title include inhibiting inflammation, alleviating gum swelling and pain, and improving oral microbial balance. It is a technical achievement in the research and development direction of oral microecology and patented strains by Zhongke Yikang. Patent No.: ZL 2022 1 0119965.7 | Patent Holder: Zhongke Yikang (Beijing) Biotechnology Co., Ltd. | Authorization Announcement No.: CN 114164157 B | Authorization Date: June 3, 2022.

01 Zhongke Yikang | Probiotic R&D Technology Invention Patent Probiotic technology related to men's health A compound probiotic fermentation composition for improving male sperm motility and its application The invention patent relates to a composite probiotic fermentation composition aimed at improving male sperm vitality and its application, reflecting Zhongke Yikang's technical layout in the research direction of probiotic fermentation compositions related to male health. The information presented here is patent technical data and does not directly equate to the clinical effects of a specific product. Patent No.: ZL 2022 1 1665868.4 | Patent Holder: Zhongke Yikang (Beijing) Biotechnology Co., Ltd. | Authorization Announcement No.: CN 116144536 B | Authorization Date: October 15, 2024.

01 Zhongke Yikang | Corporate Qualifications and Management System Management System Certification Zhongke Yikang Enterprise Management System Occupational Health and Safety Management System Certification Certificate The certificate indicates that Zhongke Yikang (Beijing) Biotechnology Co., Ltd. has passed the certification for its occupational health and safety management system, based on GB/T 45001-2020/ISO 45001:2018. The certification scope covers the sale of pre-packaged food and related activities, and can serve as a qualification document for the standardized management and construction of the occupational health and safety management system of the enterprise. Certification standard: GB/T 45001-2020 / ISO 45001:2018 | Validity period of the certificate: December 19, 2023 to December 18, 2026 | Certification body: Zhongke Yikang (Beijing) Biotechnology Co., Ltd.

01 Zhongke Yikang | Corporate Qualifications and Management System Management System Certification Zhongke Yikang Enterprise Management System Quality Management System Certification Certificate The certificate indicates that Zhongke Yikang (Beijing) Biotechnology Co., Ltd. has passed the quality management system certification, based on GB/T 19001-2016/ISO 9001:2015, reflecting the establishment of a corresponding management system in the company's relevant business processes and quality management. Certification standard: GB/T 19001-2016/ISO 9001:2015 | Validity period stated on the certificate: December 19, 2023 to December 18, 2026 | Certification body: Zhongke Yikang (Beijing) Biotechnology Co., Ltd.

01 Zhongke Yikang | Corporate Qualifications and Management System Management System Certification Zhongke Yikang Enterprise Management System Environmental Management System Certification Certificate The certificate indicates that Zhongke Yikang (Beijing) Biotechnology Co., Ltd.'s relevant management system has passed the environmental management system certification, based on GB/T 24001-2016/ISO 14001:2015, and can be used as a qualification document to demonstrate the company's environmental management system and standardized operations. Certification standard: GB/T 24001-2016/ISO 14001:2015 | Validity period stated on the certificate: December 19, 2023 to December 18, 2026 | Certification body: Zhongke Yikang (Beijing) Biotechnology Co., Ltd.

01 Synergy Power | NAD+ Product Quality Information Third-party testing report NAD+ Sublingual Tablets NAD+ Sublingual Tablets Third-Party Testing | Sample and Testing Information This page contains the testing report data for NAD+ sublingual tablets issued by Huace Testing. The sample name tested is "NAD+ Sublingual Tablets," and the sample property is recorded as a dietary supplement. The commissioning unit is He Sheng Zhi Li Health Technology (Hong Kong) Co., Ltd. This testing covers a total of 8 indicators, including lead, total arsenic, total mercury, total bacterial count, and coliform group, with specific test results available on the next page of the same report. Testing organization: Huace Testing Certification Group Co., Ltd. | CTI sample number: HCQ15367001 | Sample production date: June 14, 2025 | Sample receipt date: June 20, 2025 | Testing date: June 20, 2025 to July 5, 2025 | Testing basis: GB 16740-2014 "National Standard for Food Safety Health Food".

01 Synergy Power | NAD+ Product Quality Information Third-party testing results NAD+ Sublingual Tablets NAD+ Sublingual Tablets Third-Party Testing | 8 Test Results The page displays the results of 8 tests conducted on the same batch of NAD+ sublingual tablets. The report shows that lead, total arsenic, and total mercury were not detected; the total bacterial count was 2.2×10² CFU/g; coliforms were <0.3 MPN/g; molds and yeasts were <10 CFU/g; Staphylococcus aureus and Salmonella were not detected. All 8 test conclusions in the report are marked as "compliant." Testing organization: Huace Testing Certification Group Co., Ltd. | Testing items: Lead, total arsenic, total mercury, total bacterial count, coliforms, molds and yeasts, Staphylococcus aureus, Salmonella. The testing results are only applicable to the samples tested this time and the items listed in the report, and do not extend to represent other batches or untested indicators.

01 Synergistic Power | Technical Information Related to NAD+ Invention Patent | NAD Preparation Technology NAD+ related preparation techniques Enzymatic industrial production method of NAD The invention patent relates to a method for the industrial production of NAD using enzymatic methods, belonging to the patent technical data in the direction of NAD preparation and production processes. It can be used to demonstrate the preparation of NAD-related raw materials and the industrialization technical background, but this certificate itself does not represent that the patent is held by He Sheng Zhi Li. Patent No.: ZL 2019 8 0044066.1 | Patent Holder: Bangtai Biotechnology (Shenzhen) Co., Ltd., Bangtai Hesheng Biotechnology (Shenzhen) Co., Ltd. | Authorization Announcement No.: CN 112437813 B | Authorization Announcement Date: March 3, 2023.

01 Synergistic Power | Technical Information Related to NAD+ Invention Patent | Enzyme Engineering Technology NAD biosynthesis-related technologies Nicotinamide mononucleotide adenosyltransferase mutants, their encoding genes, and applications The invention patent relates to a mutant of nicotinamide mononucleotide adenylyltransferase, as well as its encoding gene and related applications, belonging to the research and development results of enzyme engineering and technology related to NAD biosynthesis. The page is for the display of relevant technical information only, and the specific scope of patent protection is subject to the original patent document. Patent No.: ZL 2013 1 0752930.8 | Patent Holder: Bangtai Biotechnology (Shenzhen) Co., Ltd. | Patent Application Date: December 31, 2013 | Authorization Announcement Date: April 1, 2015.

01 Synergistic Power | Technical Information Related to NAD+ Invention Patent | NAD Synthesis Technology NAD synthesis-related technologies A recombinant NAD synthase, its gene, and its applications The invention patent relates to recombinant NAD synthetase, associated genes, and their applications, reflecting the technological research and development achievements in NAD synthesis and biological preparation, which can be presented as background information on NAD-related preparation technologies. Patent No.: ZL 2019 8 0044146.7 | Patent Holder: Bangtai Bioengineering (Shenzhen) Co., Ltd., Bangtai Hesheng Biotechnology (Shenzhen) Co., Ltd. | Authorization Announcement No.: CN 112437811 B | Authorization Announcement Date: May 5, 2023.

01 Synergistic Power | Technical Information Related to NAD+ Invention Patent | NAD Purification Technology Oxidized NAD purification techniques A method for purifying oxidized β-nicotinamide adenine dinucleotide The invention patent relates to a purification method for oxidized β-nicotinamide adenine dinucleotide, belonging to the separation and purification technology of NAD-related substances, which can serve as background material for NAD preparation processes and related research and development. Patent No.: ZL 2015 1 0255149.9 | Patent Holder: Bangtai Biotechnology (Shenzhen) Co., Ltd. | Patent Application Date: May 19, 2015 | Authorization Announcement Date: November 3, 2017.

01 Synergistic Power | Technical Information Related to NAD+ Invention Patent | NAD Preparation Technology High-purity NAD related preparation technology A method for preparing high-purity NAD The invention patent relates to a method for preparing high-purity NAD, belonging to the technical achievements related to the preparation, purification, and production processes of NAD, which can be used to demonstrate the background of NAD-related raw materials and preparation technologies. The patent certificate itself does not indicate that this technology is a proprietary patent of the company. Patent No.: ZL 2018 8 0037981.3 | Patent Holder: Bangtai Bioengineering (Shenzhen) Co., Ltd., Bangtai Hesheng Biotechnology (Shenzhen) Co., Ltd. | Authorization Announcement No.: CN 111065644 B | Authorization Announcement Date: July 5, 2022.

01 Product Categories Patents / Technical Information Corresponding product name Professional document title Please explain the true connection between this image and the product, the information contained therein, the research background, or case studies in the background. Please accurately fill in the source and supplementary information according to the original patent, research, clinical or case data.